Received Feb 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 3 | LM2045 | IM / LA |
Patient previously received two Pfizer-BioNTech COVID-19 vaccinations on 06/10/2022 and 07/01/2022. This report concerns the third Pfizer COVID-19 vaccination administered on 02/03/2025. Within weeks of vaccination, caregivers noted weight loss, increased thirst (polydipsia), and nighttime urination (nocturia). By April 2025, the patient reported urinary urgency with inability to void and was later diagnosed with voiding dysfunction on 04/01/2025. At a well-child exam on 06/06/2025, urinalysis showed elevated glucose and ketones, and she was diagnosed with Type 1 Diabetes Mellitus without diabetic ketoacidosis (DKA). Patient is managed with insulin via pump and continuous glucose monitor. Type 1 Diabetes remains ongoing at time of report. 08/03/2017 (2-month vaccines: Pentacel (DTaP/IPV/Hib), Hepatitis B, Prevnar 13 (Pneumococcal), Rotateq (Rotavirus)): Following vaccination the patient developed gastrointestinal symptoms including recurrent emesis, bilious vomiting, abnormal stools with visible blood, and was diagnosed with hematochezia within 19 days of vaccination. Presented for care on 8/22/2017. 09/25/2017 (4-month vaccines: Pentacel (DTaP/IPV/Hib), Prevnar 13 (Pneumococcal), Rotateq (Rotavirus)): In the months after vaccination the patient experienced recurrent infections including acute otitis media requiring multiple courses of antibiotics. 06/10/2022 and 07/01/2022 ? COVID-19 vaccinations; 10/06/2022 - Influenza vaccination: Subsequent behavioral and attention concerns were observed in the following months, and the patient was later diagnosed with ADHD in December 2022. Early childhood vaccinations (multiple routine immunizations and annual influenza vaccines): History notable for recurrent febrile illnesses, upper respiratory infections, including croup episodes, and eczema occurring repeatedly following routine immunizations per parental records.
The patient had household exposure to confirmed streptococcal pharyngitis (mother and sibling) prior to vaccination. The patient remained asymptomatic at the time of vaccination and subsequently tested negative for streptococcal infection on 02/06/2025 (3 days post-vaccination).
History of recurrent chronic otitis media during infancy requiring multiple antibiotic courses. Prior to Type 1 diabetes diagnosis, the patient met criteria for childhood obesity (BMI between the 95th?99th percentile) for the entirety of childhood. Attention-deficit/hyperactivity disorder (ADHD) diagnosed in December 2022.
None
None
06/06/2025 Testing: Renal Function Panel - Glucose = 722 mg/dL; HbA1C >14.0 (normal <5.7%); Beta-Hydroxybutyrate = 2.07 (normal 0.02 0.27 mmol/L); TSH = 1.91 (normal 0.5 4.5 mcIU/mL); Total T4 = 7.59 (normal 4.5 10 mcg/dL); Anti-Thyroid Peroxidase AB = <9 (normal <9 IU/mL); TSH Receptor Antibody <1.1 (normal < or = 1.75 IU/L); Tissue Transglutaminase Antibodies (IGA) NEGATIVE; TTG-IgA Antibody = Negative, TTG-IgA Index Value 19.7 (negative <20, weak + 20 30, positive >30); IgA (Immunoglobulin A) = 195.3 (normal 28 180 mg/dL); Lipase = 129 (normal 10-150 U/L); Osmolality, Serum = 302 (normal 280 -300 mOsm/kg); Magnesium 1.7 (normal 1.6 - 2.3 mg/dL). MEDICAL ERROR, DID NOT RUN CORRECT ANTIBODY PANEL FOR TYPE 1 DIABETES... Autoantibody Panel that was run: Factor H - NEGATIVE, Factor B - NEGATIVE, Fluid Phase Activity (IFE) - ABNORMAL, C3Nefs - NEGATIVE, C5Nefs - NEGATIVE, C4Nefs - NEGATIVE. 06/09/2025 Testing: ZNT8Rw Ab >500 (normal <15 U/mL), Insulin Antibody <0.4 (normal <0.4 U/mL); TSH 2.66 (normal 0.5 4.3 mIU/L); Free T4 1.3 (normal 0.9 1.4 ng/dL); Thyroid Peroxidase Antibodies <1 (normal <9 IU/mL); Thyroglobulin Antibodies <1 (normal < or = 1 IU/mL),; Addison s Disease Screening 21 Hydroxylase Antibody NEGATIVE; Glucose Serum = 328; Beta-Hydroxybutyrate (OL)= 0.2; HbA1C = 13.0; IT TOOK OVER 7 MONTHS TO ADVOCATE FOR A COMPLETE ANTIBODY PANEL: 01/13/2026 Testing: ZNT8RW AB = 0.038 (normal -0.2 - 0.02 index); IA-2 = 205 (normal 0 - 5 index); MIAA = 0.018 (normal -0.2 - 0.02 index); GADA = 26 (normal 0 -20); 21-OH AB = 0.001 (normal -0.2 - 0.15 index); IgA Transglutaminase Assay = 0.001 (normal -0.2 - 0.05 index); HbA1C = 6.2%